TPN102

TPN102 is a small molecule inhibitor of voltage-gated sodium and calcium channels currently under development by Suzhou Vigonvita Biomedical for the treatment of epilepsy, including drug-resistant forms. Preclinical studies have demonstrated that TPN102 exhibits significant efficacy in multiple animal models of drug-resistant epilepsy, showing superior protective effects against seizures compared to standard treatments like topiramate and zonisamide. A key differentiator for TPN102 is its significantly lower inhibitory effect on carbonic anhydrase II (CA-II) compared to existing anti-epileptic drugs, which may reduce adverse effects related to growth and development, potentially making it more suitable for long-term use in pediatric and adolescent patients. The drug has progressed into Phase 2 clinical development in China.